SYK and acute myeloid leukemia: A phase I trial with mivavotinib (TAK-659), a dual SYK/ FLT3 inhibitor, in patients with relapsed/refractory AML revealed disrupted SYK-driven FLT3-independent support as well as activity in FLT3-mutant subsets of patients [53].